Chronic liver disease gets worse when the liver's immune system stays overactive, resulting in ongoing inflammation and ...

CK0804, a regulatory T cell therapy, received FDA orphan drug designation for myelofibrosis, supporting rare disease treatment development. Clinical study results showed significant reductions in ...

Treg therapeutic designed to preferentially traffic towards its ligand CXCL12 over expressed in the bone marrow and spleen in myelofibrosis. -- CK0804 engages with antigen presenting cells within ...

A 200,000-year-old molar from Denisova Cave has provided a glimpse into the life of Denisovans, revealing startling new ...

Novel research led by Brazilian scientists describes the immune system's reactions in detail in the first living patient to ...

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to ...

Modern medicine has reduced many infectious threats, yet bacteria and viruses still account for millions of deaths each year.

Pioneering research led by Brazilians describes the immune system's reactions in detail in the first living patient to receive a genetically modified pig kidney transplant.

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

Investigators describe this as the largest study to date linking thromboinflammation biomarkers with thrombosis risk in myeloproliferative neoplasms.

Respiratory virus season is in full gear, with flu admissions rising quickly in recent weeks, according to the latest national data from the CDC. Fourteen states reported high levels of flu-like ...